JP2021514398A5 - - Google Patents

Info

Publication number
JP2021514398A5
JP2021514398A5 JP2020566546A JP2020566546A JP2021514398A5 JP 2021514398 A5 JP2021514398 A5 JP 2021514398A5 JP 2020566546 A JP2020566546 A JP 2020566546A JP 2020566546 A JP2020566546 A JP 2020566546A JP 2021514398 A5 JP2021514398 A5 JP 2021514398A5
Authority
JP
Japan
Prior art keywords
carbon atoms
group
combination pharmaceutical
egfr inhibitor
pharmaceutical preparation
Prior art date
Application number
JP2020566546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514398A (ja
JPWO2019164945A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018770 external-priority patent/WO2019164945A1/en
Publication of JP2021514398A publication Critical patent/JP2021514398A/ja
Publication of JP2021514398A5 publication Critical patent/JP2021514398A5/ja
Publication of JPWO2019164945A5 publication Critical patent/JPWO2019164945A5/ja
Pending legal-status Critical Current

Links

JP2020566546A 2018-02-20 2019-02-20 Egfr阻害剤の組合せ医薬製剤およびその使用法 Pending JP2021514398A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862632798P 2018-02-20 2018-02-20
US62/632,798 2018-02-20
PCT/US2019/018770 WO2019164945A1 (en) 2018-02-20 2019-02-20 Pharmaceutical combinations of egfr inhibitors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2021514398A JP2021514398A (ja) 2021-06-10
JP2021514398A5 true JP2021514398A5 (https=) 2022-02-25
JPWO2019164945A5 JPWO2019164945A5 (https=) 2022-02-25

Family

ID=67686991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566546A Pending JP2021514398A (ja) 2018-02-20 2019-02-20 Egfr阻害剤の組合せ医薬製剤およびその使用法

Country Status (6)

Country Link
US (1) US20210077469A1 (https=)
EP (1) EP3755330A4 (https=)
JP (1) JP2021514398A (https=)
AU (1) AU2019225803A1 (https=)
CA (1) CA3088972A1 (https=)
WO (1) WO2019164945A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12377080B2 (en) 2019-06-21 2025-08-05 Dana-Farber Cancer Institute, Inc. Allosteric EGFR inhibitors and methods of use thereof
JP7561777B2 (ja) * 2019-06-21 2024-10-04 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 新規egfr阻害剤
IL326879A (en) 2019-11-11 2026-04-01 Dana Farber Cancer Inst Inc EGFR allosteric inhibitors and methods of using them
CN111592535B (zh) * 2020-06-22 2021-07-20 通化师范学院 一种抗egfr突变的抑制剂eai045的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049518B1 (en) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
WO2012129562A2 (en) * 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN103702990B (zh) * 2011-07-27 2015-09-09 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
CA2987914C (en) * 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
EP3445357B1 (en) * 2016-04-22 2021-05-26 Dana-Farber Cancer Institute, Inc. Bifunctional molecules for degradation of egfr and methods of use

Similar Documents

Publication Publication Date Title
JP2021514398A5 (https=)
JP2021514011A5 (https=)
AU2013213260B2 (en) Imidazopyrrolidinone compounds
JP5579715B2 (ja) cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ
JP2021514400A5 (https=)
JP2003500404A5 (https=)
AR087336A1 (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
RU2014105624A (ru) Соединения индазола, способ их применения и фармацевтическая композиция
SI3106463T1 (en) Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase
RU2004106783A (ru) Производные 4-амино-6-фенилпирроло[2, 3] пиримидина
JP2019519586A5 (https=)
RU2004132844A (ru) Производные бензамида, полехные в качестве ингибиторов деацетилазы гистонов
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
JP2007519694A5 (https=)
JP2009536620A5 (https=)
RU2008144806A (ru) 4-анилинохинолин-3-карбоксамиды в качестве ингибиторов csf-1r киназы
MY189118A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives
JP2011507854A5 (https=)
RU2002129557A (ru) Производные 8-хинолинксантина и 8-изохинолинксантина в качестве ингибиторов фосфоэстеразы pde5
RU2009119181A (ru) Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3
JP2017501983A5 (https=)
JP2018522861A5 (https=)
JP2021518379A5 (https=)
RU2009103300A (ru) Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии
RU2012133686A (ru) Арилсульфамидные производные пиридинопиридинонов, их получение и их применение в терапии